Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027)

被引：0
|
作者：
Lai, Ching-Lung
Chang, Ting-Tsung
Chao, You-Chen
Tanwandee, Tawesak
Thongsawat, Satawat
Lee, Shou-Dong
Angus, Peter
Zink, Richard
Zhu, Jin
Brett-Smith, Helena
Neo, Boon-Leong
机构：
[1] Queen Mary Hosp, Hong Kong 70101, Peoples R China
[2] Natl Cheng Kung Univ, Coll Med, Tainan, Taiwan
[3] Tri Serv Gen Hosp, Taipei 10700, Taiwan
[4] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand
[5] Maharajnakorn Chiang Mai Hosp, Chiang Mai, Thailand
[6] Taipei Vet Gen Hosp, Taipei, Taiwan
[7] Austin & Repatriation Med Ctr, West Heidelbrg, Vic, Australia
[8] Bristol Myers Squibb Pharmaceut Res Inst, Wallingford, CT USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A128 / A128
页数：1
相关论文
共 50 条
  • [1] Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Lai, Ching-Lung
    Chang, Ting-Tsung
    Chao, You-Chen
    Tanwandee, Tawesak
    Thongsawat, Satawat
    Lee, Shou-Dong
    Angus, Peter
    Zink, Richard
    Zhu, Jin
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A31 - A31
  • [2] Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Shouval, D.
    Akarca, U. S.
    Hatzis, G.
    Kitis, G.
    Lai, C. L.
    Cheinquer, H.
    Chang, T. T.
    Zink, R.
    Zhu, J.
    Brett-Smith, H.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S21 - S22
  • [3] Continued virologic improvement through 96 weeks of Entecavir treatment in HBeAg(-) chronic hepatitis B patients (STUDY ETV-027)
    Poordad, Fred
    Dieterich, Douglas T.
    Min, Albert D.
    Shouval, Daniel
    Lai, Ching-Lung
    Cheinquer, Hugo
    Chang, Ting-Tsung
    Zink, Richard
    Zhu, Jin
    Brett-Smith, Helena
    GASTROENTEROLOGY, 2006, 130 (04) : A848 - A848
  • [4] Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Manns, M.
    Shouval, D.
    Akarca, U. S.
    Hatzis, G.
    Kitis, G.
    Zink, R.
    Zhu, J.
    Brett-Smith, H.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S86 - S86
  • [5] Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Akarca, U.
    Hatzis, G.
    Kitis, G.
    Shouval, D.
    Lai, C.
    Cheinquer, H.
    Chang, T.
    Zink, R.
    Zhu, J.
    Brett-Smith, H.
    LIVER INTERNATIONAL, 2006, 26 : 5 - 5
  • [6] Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)
    Yurdaydin, C.
    Sollano, J.
    Hadziyannis, S.
    Kaymakoglu, S.
    Sherman, M.
    Brett-Smith, H.
    Vaughan, J.
    Hindes, R. G.
    LIVER INTERNATIONAL, 2006, 26 : 14 - 14
  • [7] Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022)
    Gish, RG
    Chang, TT
    De Man, RA
    Gadano, A
    Sollano, J
    Han, K
    Lok, A
    Zhu, J
    Cross, A
    Brett-Smith, H
    Fernandes, L
    HEPATOLOGY, 2005, 42 (04) : 267A - 268A
  • [8] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Sollano, J.
    De Man, R. A.
    Mutimer, D.
    Gish, R. G.
    Chang, T. -T.
    Zhu, J.
    Cross, A.
    Brett-Smith, H.
    LIVER INTERNATIONAL, 2006, 26 : 6 - 7
  • [9] Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)
    Yurdaydin, C.
    Sollano, J.
    Hadziyannis, S.
    Kaymakoglu, S.
    Sherman, M.
    Brett-Smith, H.
    Vaughan, J.
    Hindes, R. G.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S36 - S36
  • [10] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    De Man, R. A.
    Mutimer, D.
    Gish, R.
    Chang, T.
    Zhu, J.
    Cross, A.
    Brett-Smith, H.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S89 - S89
12345